Biotech Funding Deals and Partnerships: Analysis of Recent Venture Capital and Corporate Capital Funding and Other Transactions

May 20, 2014
156 Pages - Pub ID: KLI5248409
Share this report
 
Online Download $3,500
Departmental Site License (one location, 10 users) $5,000
Global Site License $7,000
Recent Biotech Funding, Deals and Partnerships

Nearly one out of every 8 dollars invested in companies are invested in biotech. Biotech investment has increased significantly in the past few years, and 2013 saw a notable spike. In the last few years, this has resulted in a complex series of deals and transactions, ranging from complete buyouts, to licensing transactions, to a variety of collaborative arrangements. In addition to this influx of corporate capital, biotechnology companies have seen a significant influx of venture capital, as investors invest in new science and technology that they believe have potential in the clinic.

This Kalorama Information report, Recent Biotech Funding Deals and Partnerships, attempts to provide clarity on the phenomenon. The report analyzes the recent, current and potential landscape for investing in the biotechnology sector.

Included in the report's coverage are the following data points
  • 56 Key Biotech Deals Analyzed: Financial Details and Therapeutic Potential
  • Venture Capital Dollar Trends, Overall Dollars Invested 2009-2013 (in US billions)
  • Health Care as a Percentage of Total Venture Investment, 2009-2012 (in US billions)
  • Biotech Companies Raising Series A Dollars, 2009-2012, Greater than $2 Million
  • Number of Biotech Series A Companies by Indication Oncology,
  • Platform Discovery, Diagnostics, CNS, Autoimmune)
  • Biotech Total Deal Value, 2005-2012
  • IPO Statistics
  • Personalized Medicine Disclosed M&A Number of Deals by Focus, 2010-2013
Analyzed are both venture and corporate capital funding efforts. In addition, the report looks at other collaborative approaches, including licensing, joint ventures and partnerships aimed at moving product candidates into the market place as approved therapies, especially if they address unmet medical needs.

This report also reviews the nature and direction of funding trends, and reviews the important role that investments play in moving technology into the market place. The report profiles several biotechnology sector companies and the deals that they were involved in from 2011 to 2014. Some of the companies and transactions profiled in the report include: Alkermes, Boston Biomedical, Dicerna Pharmaceuticals, immatics biotechnologies, Micromet, Reata Pharmaceuticals, UCB and Xoma.

The information presented in this report is the result of data gathered from company product literature and other corporate brochures and documents, as well as information found in the scientific and trade press. In addition, interviews were conducted with executives and analysts.

The following are among the companies covered in this report:
  • Abbott
  • AC Immune SA
  • Adimab
  • Aileron Therapeutics Inc.
  • Atara Biotherapeutics
  • Cellectis
  • Clarus Ventures
  • CoStim Pharmaceuticals
  • Covagen AG
  • Dicerna Pharmaceuticals Inc.
  • Editas Medicine
  • Enanta Pharmaceuticals Inc.
  • Endocyte Inc.
  • Evotec
  • Forma Therapeutics
  • Galapagos NV
  • Mannkind Corp.
  • Melinta Therapeutics
  • Micromet
  • Novartis
  • OncoMed
  • Onyx Pharmaceuticals Inc.
  • Otonomy Inc.
  • Pharmasset
  • Seattle Genetics Inc.
  • Royalty Pharma
  • Roche
  • Sutro Biopharma Inc.
  • Thesan Pharmaceuticals Inc.
  • UCB Inc.
  • Voyager Therapeutics
  • Xenon Pharmaceuticals Inc.
  • Xoma Corp.
1.0 EXECUTIVE SUMMARY
1.1 Key Findings
1.2 Methodology
2.0 INTRODUCTION
2.1 Reason for the Report
2.1.1 Why Investing Is Important
2.1.2 Beyond the Seed Stage
2.1.3 Identify Value Drivers
3.0 TRENDS AND EXPECTATIONS
3.1 Corporate Venture Capital Spurs M&A Activity
3.2 Licensing Deals to Grow
3.3 Venture Capital's Strong Outlook
3.4 Therapeutic Areas of Focus
3.4.1 The Outcomes Push
3.5 In Need of New Strategies
3.5.1 Modeling Potential Success
3.5.2 Crowdfunding
3.5.2.1 A Lifeline
4.0 GROWTH THROUGH SOPHISTICATED COLLABORATIONS
4.1 Determining Product Value
4.1.1 Quantifiable Issues
4.1.2 Revolutionary Value
4.1.3 Global Value
4.2 Changing Roles and Market Landscapes
5.0 VENTURE CAPITAL VS. CORPORATE CAPITAL
5.1 New Fundraising Vistas
5.2 Venture Arms with a Strategy
5.3 Corporate Capital Fundamentals
6.0 INVESTMENT DOLLAR TRENDS
6.1 Annual Numbers
6.1.1 Trends in 2013
6.1.2 Trends in 2012
6.1.3 Trends in 2011
6.1.4 Trends in 2010
6.1.5 Trends in 2009
6.2 Personalized Medicine
7.0 KEY DEALS
7.1 Ablynx NV
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.2 Acetylon Pharmaceuticals Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.3 AC Immune SA
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.4 Adimab
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.5 Aileron Therapeutics Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.6 Algeta ASA
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.7 Alios BioPharma Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.8 Alkermes
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.9 Alnylam Pharmaceuticals
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.10 Amylin Pharmaceuticals
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.11 Ardea Biosciences
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.12 Atara Biotherapeutics
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.13 Avila Therapeutics
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.14 Boston Biomedical
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.15 Cellectis
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.16 Clarus Ventures
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.17 CoStim Pharmaceuticals
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.18 Covagen AG
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.19 Dicerna Pharmaceuticals Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.20 Editas Medicine
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.21 Enanta Pharmaceuticals Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.22 Endocyte Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.23 Evotec AG
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.24 Forma Therapeutics
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.25 Galapagos NV
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.26 Gemin X Pharmaceuticals
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.27 Genmab
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.28 GlaxoSmithKline
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.29 Human Genome Sciences
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.30 immatics Biotechnologies GmbH
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.31 Inhibitex
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.32 Inhibrx
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.33 Isis Pharmaceuticals Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.34 Juno Therapeutics
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.35 Macrogenics Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.36 Mannkind Corp.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.37 Medigene AG
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.38 Melinta Therapeutics
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.39 Merck
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.40 Mesoblast Ltd.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.41 Micromet AG
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.42 Moderna Therapeutics Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.43 OncoMed Pharmaceuticals Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.44 Onyx Pharmaceuticals Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.45 Otonomy Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.46 Pharmasset
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.47 Plexxikon Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.48 Reata Pharmaceuticals
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.49 Royalty Pharma
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.50 Seattle Genetics Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.51 Sutro Biopharma Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.52 Thesan Pharmaceuticals Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.53 UCB Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.54 Voyager Therapeutics
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.55 Xenon Pharmaceuticals Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.56 Xoma Corp.
Description of Deal
Size
Agreement Type
Details
LIST OF EXHIBITS
1.0 EXECUTIVE SUMMARY
Summary Exhibit: Biotechnology Investment Dollars, 2012 and 2013 ($ millions)
6.0 INVESTMENT DOLLAR TRENDS
Exhibit 1: Venture Capital Dollar Trends, Overall Dollars Invested 2009-2013
Exhibit 2: Venture Capital Dollar Trends, Overall Dollars Invested 2009-2013
Exhibit 3: Venture Capital Dollar Trends, Biotechnology Dollars Invested 2009-2013
Exhibit 4: Venture Capital Dollar Trends, Biotechnology Dollars Invested 2009-2013
Exhibit 5: Breakdown of Overall and Biotech Venture Capital Dollars, Billions of Dollars US Invested in 2013
Exhibit 6: Venture Capital Dollar Trends, Biotechnology Dollars Invested by Quarter, 2009-2013
Exhibit 7: Health Care as a Percentage of Total Venture Investment, 2009-2012
Exhibit 8: Biotech Companies Raising Series A Dollars, 2009-2012, Greater than $2 Million
Exhibit 9: Number of Biotech Series A Companies by Indication, 2009, Raising More than $2 Million
Exhibit 10: Number of Biotech Series A Companies by Indication, 2010, Raising More Than $2 Million
Exhibit 11: Number of Biotech Series A Companies by Indication, 2011, Raising More Than $2 Million
Exhibit 12: Number of Biotech Series A Companies by Indication, 2012, Raising More Than $2 Million
Exhibit 13: Biotech Total Deal Value, 2005-2012, Minimum Two Big Exits
Exhibit 14: Personalized Medicine M&A with Disclosed Values, 2010-2013
Exhibit 15: Personalized Medicine Disclosed M&A Number of Deals by Focus, 2010-2013
Exhibit 16: Personalized Medicine Disclosed M&A Deal Value by Focus, 2010-2013
Exhibit 17: Personalized Medicine Financings, 2010-2013
Exhibit 18: Personalized Medicine Financings by Type, Number of Deals, 2010-2013
Exhibit 19: Personalized Medicine Financings by Category, Number of Deals, 2010-2013

In this report, {{keyword[keywordTextProperty]}} appears {{keyword[keywordCountProperty]}} times. {{searchResults.STATRESULT.SUMMARY.KW[keywordTextProperty]}} appears {{searchResults.STATRESULT.SUMMARY.KW[keywordCountProperty]}} times.

We were unable to search inside this report.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.